Dr Chris Pollard

Chris has a background in physiology and pharmacology, with particular focus on ion channels. After ion channel-based post-docs at the Universities of London and Newcastle, he started his pharmaceutical company career in 1990 at Fisons, which became Astra and then AstraZeneca. Until 2001 he focussed on ion channels as efficacy targets for respiratory diseases but since then has focussed on ion channels in the context of cardiovascular safety. In recent years his role has broadened such that he now leads AstraZeneca’s cardiovascular safety strategy.